

About Cytomegalovirus (CMV)

FOR PEDIATRIC CARE PROVIDERS

**The Role of the Primary Healthcare Provider in Congenital Cytomegalovirus (CMV) Screening and Follow-up Recommendations and Monitoring**

On January 1, 2016, C.G.S. Sec. 19a-55 was amended to require every Connecticut-born infant who fails their newborn hearing screening also be screened for congenital Cytomegalovirus (CMV), as soon after birth as is medically appropriate. **†** This law also requires each institution caring for newborns (e.g. birthing facilities) to report any cases of CMV to the Department of Public Health.  The full statute can be viewed here: <https://www.cga.ct.gov/current/pub/chap_368a.htm#sec_19a-55>.

**Why was C.G.S. Sec. 19a-55 amended and what is the benefit?**

* **Congenital CMV is the most common cause of nonhereditary sensorineural hearing loss (SNHL).**
* The national Joint Committee on Infant Hearing (JCIH) recommends all infants be screened for hearing loss by no later than 1 month of age to maximize the outcome for infants who are deaf or hard of hearing. Connecticut hospitals conduct two hearing screenings prior to discharge. If either ear does not pass after a second inpatient hearing screening prior to 21 days of age, CMV testing is warranted before discharge. This protocol allows for more timely determination of the presence, cause, and nature of hearing loss; as well as for education on the research and possible intervention strategies if congenital CMV is involved.
* Infants with asymptomatic CMV outnumber those that show symptoms 3 to 1. In a large number of children with asymptomatic congenital CMV, hearing loss is the only sequela.
* Research has shown that approximately 50% of hearing loss from congenital CMV infection is either late-onset or progressive in nature.

**When and how should infants who failed their hearing screening be tested for CMV?**

To identify infants at risk for congenital CMV-associated progressive hearing loss, infants who fail the second hearing screening, unilaterally or bilaterally, should be tested for CMV prior to discharge from the hospital. This can be performed with a PCR assay for CMV on urine or saliva or via urine culture. After 3 weeks of age, these tests cannot differentiate between congenital CMV and CMV acquired postnatally. Postnatal CMV rarely causes symptoms and is not associated with hearing loss.

**What action should be taken if an infant has a positive congenital CMV test?**

The primary healthcare provider is responsible for relaying these test results to the baby’s parents or guardian.  Other than necessary follow-up with an audiologist, the further management of babies who are CMV positive is not well-defined.  In particular, there are no official recommendations regarding the need to treat such babies with valganciclovir, an anti-viral shown to be effective in treating CMV infections of various kinds. Clinical trials of symptomatic babies infected with CMV congenitally have demonstrated improved hearing and neurodevelopment outcomes if treatment is started within the first 28 days of life; but such studies have not specifically addressed infants with sensorineural hearing loss as the sole presenting finding. Studies are ongoing to determine what types of therapy are of greatest benefit to CMV-infected infants. Infants with suspected congenital CMV infections should be evaluated by physicians who specialize in these infections. Call the Pediatric Infectious Diseases Department at Yale (877-925-3637) or Connecticut Children's Medical Center (860-545-9490) to make an “urgent appointment” for the patient.

**Ongoing hearing monitoring is essential.** Although there is not a universal consensus, a general recommendation for **all** babies with congenital CMV (regardless of their newborn hearing screening results) is to have a hearing re-assessment no later than 3 months after occurrence and every 12 months to age 3; however, each child should be considered on an individual basis as the timing of assessments may need to be more frequent or altered based on antiviral therapy, rehabilitation needs, pediatric audiologist guidance, or parent concerns. CMV-associated congenital hearing loss may be progressive in nature. These infants should undergo a diagnostic audiological testing as soon as possible.

**Birth to Three System** services are available for children under age three who live in Connecticut that are diagnosed with CMV. Anyone involved in the child’s care can refer them to B23. To refer a child, go to [www.b23.org/referral](http://www.b23.org/referral) or call 800-505-7000.

**What action should be taken if an infant fails their newborn hearing screening?**

**ALL** infants who fail the second newborn hearing screen, regardless of their CMV status, should have a full audiological evaluation **as soon as possible** with an audiologist possessing expertise in the evaluation and management of pediatric hearing loss.

The following is the list of audiology centers that conduct the test battery recommended by the Connecticut Early Hearing Detection and Intervention Task Force for the diagnostic hearing testing of infants who do not pass the hearing screening conducted at birth:

* Connecticut Children’s Medical Center (Hartford, Farmington, or Glastonbury), (860) 545-9642
* Lawrence & Memorial Hospital, Waterford Outpatient Rehabilitation Services, (860) 271-4900
* University of Connecticut, Speech & Hearing Clinic (Storrs), (860) 486-2629
* Yale New Haven Children’s Hospital (New Haven), (877) 925-3637

These infants should undergo a **complete diagnostic audiological evaluation** as soon as possible.

***CMV-associated congenital hearing loss may be progressive in nature.***

**What other conditions place a child at risk for late-onset\progressive hearing loss?**

Other newborn risk factors for progressive or late-onset hearing loss include:

* NICU stay for more than 5 days (or exposure to ototoxic medications, mechanical ventilation,

ECMO, or hyperbilirubinemia requiring exchange transfusion)

* Family history of permanent childhood hearing loss
* Other prenatal infections such as herpes, toxoplasmosis, syphilis, or rubella

The JCIH recommends that these infants also undergo frequent hearing assessment through early childhood by a pediatric audiologist by 9 months of age, as hearing loss may develop over time even though the initial hearing screen may have been passed. However, the timing and frequency of follow up should be individualized as recommended by a qualified pediatric audiologist.

**Where can I get more information on CMV and preventing CMV?**

[www.ct.gov/dph/ehdi](http://www.ct.gov/dph/cwp/view.asp?a=3138&q=387718&dphNav_GID=1971) [www.cdc.gov/cmv](http://www.cdc.gov/cmv/index.html) [www.nationalcmv.org](http://www.nationalcmv.org)

Connecticut Early Hearing Detection and Intervention Program at (860) 509-8251 or https://portal.ct.gov/ehdi

***†****Note – At the time of publishing, there was newly passed CMV legislation that will take effect in 2025.*

This resource has been adapted from the Utah Department of Health’s version. The original facts were compiled by the CMV Core Facts Committee for Utah H.B. 81 (2013 General Session) UCA 26-10-10 Cytomegalovirus Public Health Initiative. 08\_2023 version